Integrating Barostim into a Comprehensive Heart Failure Program

Despite the use of guideline-directed medical therapy, many patients with HFrEF continue to experience worsening symptoms and disease progression. Barostim works with GDMT by stimulating the carotid baroceptors to improve heart failure symptoms.  In this symposium, an experienced faculty will discuss unmet needs with GDMT and device therapy in class II/III heart failure patients, Barostim patient selection, post-implant management, and patient care pathways, and real world strategies for incorporating Barostim into a comprehensive heart failure program

Sponsored by CVRx